Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
  • Publication number: 20130150311
    Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.
    Type: Application
    Filed: December 13, 2011
    Publication date: June 13, 2013
    Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
  • Publication number: 20130144250
    Abstract: A method of treatment, such as treating an estrogen-related disorder or a psychotic disorder, by implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of an active pharmaceutical ingredient (such as an aromatase inhibitor or risperidone) to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes an active pharmaceutical ingredient and optionally, a sorption enhancer.
    Type: Application
    Filed: October 24, 2012
    Publication date: June 6, 2013
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventor: Endo Pharmaceuticals Solutions Inc.
  • Patent number: 8445542
    Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: May 21, 2013
    Assignee: Bridge Pharma, Inc.
    Inventor: A. K. Gunnar Aberg
  • Publication number: 20130123172
    Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 16, 2013
    Applicant: DIAPIN THERAPEUTICS LLC
    Inventor: DIAPIN THERAPEUTICS LLC
  • Publication number: 20130123366
    Abstract: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 16, 2013
    Applicant: The Ohio State University Research Foundation
    Inventor: The Ohio State University Research Foundation
  • Patent number: 8440863
    Abstract: The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: May 14, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx
  • Patent number: 8435497
    Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 7, 2013
    Assignee: Takeda GmbH
    Inventors: Klaus Dietzel, Helgert Mueller
  • Publication number: 20130104881
    Abstract: Pharmaceutical pressurized metered dose inhalers are disclosed having improved temperature and moisture stability comprising CFC-free, ethanol-free compositions that include lactose of particle diameter larger than 1 ?m as a means of minimizing sticking to the walls and other destabilization mechanisms activated by moisture ingress from the environment.
    Type: Application
    Filed: October 31, 2011
    Publication date: May 2, 2013
    Applicant: Laboratorio Pablo Cassara S.R.L.
    Inventors: Fernando Toneguzzo, Julio Cesar Vega
  • Publication number: 20130109674
    Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 2, 2013
    Applicant: Achelios Therapeutics LLC
    Inventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
  • Publication number: 20130102683
    Abstract: The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 25, 2013
    Applicant: RATIOPHARM GMBH
    Inventors: Jana Paetz, Sandra Brueck
  • Publication number: 20130102682
    Abstract: The invention relates to an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution. The invention also relates to granules and pharmaceutical formulations containing fingolimod in the form of a solid solution in matrix material. The subject matter of the invention further relates to methods of preparing a solid solution of fingolimod or of an intermediate, and also granules and pharmaceutical formulations containing fingolimod in the form of a solid solution.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 25, 2013
    Applicant: Ratiopharm GMBH
    Inventors: Jana Paetz, Dominique Meergans
  • Publication number: 20130095177
    Abstract: The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 18, 2013
    Applicant: RATIOPHARM GMBH
    Inventors: Jana Paetz, Katrin Rimkus
  • Publication number: 20130095156
    Abstract: The invention provides disintegratable films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a glucose component, a filler, a plasticizer and/or humectant. The films are preferably in the form of a mucoadhesive monolayer having a thickness sufficient to rapidly disintegrate in the oral environment and release the active ingredient without undue discomfort to the oral mucosa. The monolayer can be cut to any desired size or shape to provide conveniently useable unit dosage forms for administration to oral or other mucosal surfaces for human pharmaceutical, cosmetic, or veterinary applications. The invention further provides methods of administering the film compositions by placing the composition into, for example, the oral cavity for a sufficient period of time to permit the film to disintegrate and release the active ingredient.
    Type: Application
    Filed: December 10, 2012
    Publication date: April 18, 2013
    Applicant: Adhesives Research, Inc.
    Inventor: Adhesives Research, Inc.
  • Publication number: 20130096126
    Abstract: A method for enhancing learning or memory of both in a mammal having impaired learning or emory of both from a neuro-degenerative disorder, which entails the step of administering at least one compound or a salt thereof which is a ?1-adrenergic receptor agonist, partial agonist or receptor ligand in an amount effective to improve the learning or memory or both of said mammal.
    Type: Application
    Filed: April 22, 2011
    Publication date: April 18, 2013
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mehrdad Shamloo, Mehrdad Faizi, William Mobley
  • Patent number: 8420625
    Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: April 16, 2013
    Assignee: Lithera, Inc
    Inventor: John Daniel Dobak
  • Publication number: 20130090295
    Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: April 11, 2013
    Applicant: BRIDGE PHARMA, INC.
    Inventor: BRIDGE PHARMA, INC.
  • Patent number: 8415397
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 9, 2013
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Publication number: 20130084340
    Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 4, 2013
    Applicant: NEOS THERAPEUTICS, LP
    Inventors: Mark Tengler, Paul Taskey, Daniel Lockhart, Russell McMahen
  • Publication number: 20130084343
    Abstract: Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more RNAs associated with sepsis are also provided. Compositions and kits are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 4, 2013
    Applicant: CEPHEID
    Inventors: David Vilanova, Olivier Delfour
  • Publication number: 20130079309
    Abstract: The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.
    Type: Application
    Filed: March 3, 2011
    Publication date: March 28, 2013
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Joe G.N. Garcia, Steven M. Dudek
  • Publication number: 20130074834
    Abstract: A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.
    Type: Application
    Filed: November 21, 2012
    Publication date: March 28, 2013
    Applicant: CIPLA LIMITED
    Inventor: Cipla Limited
  • Publication number: 20130079344
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Application
    Filed: March 14, 2012
    Publication date: March 28, 2013
    Applicant: OMEROS CORPORATION
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Publication number: 20130072567
    Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Applicant: NORGINE BV
    Inventor: Norgine BV
  • Publication number: 20130071440
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 21, 2013
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Publication number: 20130065885
    Abstract: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 14, 2013
    Applicant: IMAGINOT PTY LTD.
    Inventors: Michael Stephen Roberts, Ruoying Jiang, Keivan Bezanehtak, Greg Andrew Davey, George Alexander Davidson, Geraldine Ann Elliott, Stephen Douglas Chandler, Mantu Sarkar
  • Publication number: 20130065954
    Abstract: The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder.
    Type: Application
    Filed: November 8, 2012
    Publication date: March 14, 2013
    Applicant: NOVARTIS AG
    Inventor: NOVARTIS AG
  • Publication number: 20130059821
    Abstract: Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors.
    Type: Application
    Filed: September 10, 2012
    Publication date: March 7, 2013
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Patent number: 8383681
    Abstract: The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 26, 2013
    Assignee: Chelsea Therapeutics, Inc.
    Inventors: Michael J. Roberts, Simon Pedder
  • Patent number: 8383685
    Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: February 26, 2013
    Assignee: Bridge Pharma, Inc.
    Inventor: A. K. Gunnar Aberg
  • Patent number: 8372888
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 12, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
  • Patent number: 8367734
    Abstract: A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: February 5, 2013
    Assignee: Amphastar Pharmaceuticals Inc.
    Inventors: Jianxin Gao, James Luo, Rong Zhou, Mary Ziping Luo, Jack Yongfeng Zhang
  • Publication number: 20130028845
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: October 2, 2012
    Publication date: January 31, 2013
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20130028977
    Abstract: The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 31, 2013
    Applicant: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Sunil Sudhakar Chaudhari
  • Publication number: 20130022654
    Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
    Type: Application
    Filed: February 7, 2011
    Publication date: January 24, 2013
    Applicant: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
  • Publication number: 20130018077
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicant: Acucela Inc.
    Inventors: Ian Leslie Scott, Vladmir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Publication number: 20130017190
    Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.
    Type: Application
    Filed: August 6, 2012
    Publication date: January 17, 2013
    Inventor: Betty C. Soliven
  • Publication number: 20130017267
    Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.
    Type: Application
    Filed: September 20, 2012
    Publication date: January 17, 2013
    Applicant: Vectura Limited
    Inventor: Vectura Limited
  • Publication number: 20130017229
    Abstract: The invention provides a composition whose porosity, pore size, pore connectivity, swelling agent concentration, and/or specific volume undergoes a change from a first value to a second value in response to an electromagnetic signal, the composition having a matrix material in which is distributed a magnetic material.
    Type: Application
    Filed: December 15, 2010
    Publication date: January 17, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: David J. Mooney, Xuanhe Zhao
  • Publication number: 20130012502
    Abstract: Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.
    Type: Application
    Filed: December 7, 2010
    Publication date: January 10, 2013
    Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Manuel Rosa-Calatrava, Jean-Jacques Diaz, Julien Textoris, Laurence Josset
  • Publication number: 20130005799
    Abstract: This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogues for the treatment of a tumor expressing a ?2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a ?2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analogue or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.
    Type: Application
    Filed: March 10, 2011
    Publication date: January 3, 2013
    Inventors: Irving W. Wainer, Michel Bernier, Lawrence Robert Toll, Lucita Arenas Jimenez
  • Publication number: 20130005823
    Abstract: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended to deter abuse of the active drug substance via injection, nasal inhalation or consumption of quantities of the dosage unit exceeding the usual therapeutically effective dose.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 3, 2013
    Applicant: ACURA PHARMACEUTICALS, INC.
    Inventors: James F. EMIGH, Ronald L. LEECH, JR., Andrew D. REDDICK, Ron J. SPIVEY
  • Publication number: 20130005740
    Abstract: Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80° C. to produce a first mixture. A gelling agent and water is also provided and heat to at least 80° C. to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112° C. to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90° C. for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product.
    Type: Application
    Filed: August 5, 2010
    Publication date: January 3, 2013
    Applicant: 7267207 CANADA LIMITED CORPORATION
    Inventors: Stuart A. Lowther, Real Plante, Bradley H. Pilon, Mark A. Tarnopolsky
  • Publication number: 20120329879
    Abstract: Provided herein are methods for improving function in a retinal cell associated with a diabetic condition and for treating a diabetic retinopathic condition in a subject. The methods comprise contacting the retinal cell or administering to the subject a beta-adrenergic receptor agonist or R-isomer thereof such as have the chemical structural formula: where R1 is (CH2)n(CH3)2 or where n is 1 to 4, R2 is H or H.HX, where X is a halide and R3 is O(CH2)mCH3 at one or more of C2-C6, where m is 0 to 4. Also provided are BAR agonists having the structural where R1 is the (CH2)n-phenyl-R2 substituent and the hydroxy-benzene moiety is 1,2-benzene diol or 1,3-benzene diol.
    Type: Application
    Filed: September 7, 2012
    Publication date: December 27, 2012
    Applicant: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jena J. Steinle, Kimberly P. Williams, Jayaprakash Pagadala, Duane D. Miller
  • Publication number: 20120328664
    Abstract: Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.
    Type: Application
    Filed: September 7, 2012
    Publication date: December 27, 2012
    Inventors: Vivian Georgousis, Wei-Qin Tong
  • Publication number: 20120322884
    Abstract: The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.
    Type: Application
    Filed: March 1, 2011
    Publication date: December 20, 2012
    Applicants: UNIVERSITY OF MANITOBA, NOVA SOUTHEASTERN UNIVERSITY
    Inventors: Mutasem Rawas-Qalaji, Enrique Nieves, Keith John Simons, Frances Estelle Reed Simons, Ousama Rachid
  • Publication number: 20120316246
    Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.
    Type: Application
    Filed: July 17, 2012
    Publication date: December 13, 2012
    Inventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
  • Publication number: 20120308613
    Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.
    Type: Application
    Filed: April 25, 2012
    Publication date: December 6, 2012
    Applicant: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzno Ferrarini
  • Publication number: 20120309840
    Abstract: The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia.
    Type: Application
    Filed: April 3, 2012
    Publication date: December 6, 2012
    Applicant: Gruenenthal GmbH
    Inventors: Thomas CHRISTOPH, Jean De Vry, Thomas Tzschentke, Petra Bloms-Funke, Klaus Schiene, Michel Hamon
  • Publication number: 20120308617
    Abstract: The present invention includes a method for delivering medications deeper into the lungs and to the medications' pulmonary targets, which include bronchioles and alveoli. A first particularly preferred embodiment of the invention describes the use of two steps for delivery of a medication. In a first step, an aerosolized therapeutic composition or medication is administered into a patient's respiratory tract, wherein the patient may be any animal or human subject. Following the first step, an aerosolized surfactant is administered into the patient's respiratory tract that facilitates delivery of the aerosolized medication of the first step to the medication's pulmonary target. Another embodiment of the present invention contemplates an apparatus for the delivery of an aerosolized surfactant used that facilitates delivery of previously inhaled aerosolized medication.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 6, 2012
    Inventors: Shailaja Somaraju, Julie Suman, Sudipta Ganguly, Richard Balby
  • Publication number: 20120309729
    Abstract: The invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising applying ultrasound to the substantially dry solid material.
    Type: Application
    Filed: October 20, 2010
    Publication date: December 6, 2012
    Inventors: Graham Ruecroft, Dipesh Parikh